全文获取类型
收费全文 | 280篇 |
免费 | 3篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 2篇 |
基础医学 | 9篇 |
口腔科学 | 5篇 |
临床医学 | 26篇 |
内科学 | 86篇 |
皮肤病学 | 1篇 |
神经病学 | 14篇 |
外科学 | 8篇 |
综合类 | 17篇 |
预防医学 | 16篇 |
药学 | 76篇 |
中国医学 | 2篇 |
肿瘤学 | 22篇 |
出版年
2023年 | 10篇 |
2022年 | 37篇 |
2021年 | 29篇 |
2020年 | 23篇 |
2019年 | 31篇 |
2018年 | 18篇 |
2017年 | 19篇 |
2016年 | 17篇 |
2015年 | 5篇 |
2014年 | 19篇 |
2013年 | 12篇 |
2012年 | 11篇 |
2011年 | 10篇 |
2010年 | 4篇 |
2009年 | 9篇 |
2008年 | 3篇 |
2007年 | 6篇 |
2006年 | 3篇 |
2005年 | 2篇 |
2004年 | 4篇 |
2003年 | 2篇 |
2001年 | 5篇 |
1999年 | 3篇 |
1998年 | 2篇 |
1996年 | 1篇 |
排序方式: 共有285条查询结果,搜索用时 31 毫秒
51.
52.
ObjectivesTo investigate polypharmacy and potentially inappropriate medications (PIMs) in elderly patients visiting the urology department for lower urinary tract symptoms (LUTS).MethodsWe retrospectively analyzed digital medical records of individuals over the age of 65 who visited the urology department for LUTS. This cross-sectional study was conducted in 10 hospitals located in South Korea, between September 2017 and December 2017. All prescribed medications were analyzed using electronic medical records. The updated 2015 Beers criteria were used to identify and assess the appropriateness of the prescribed drugs in elderly patients.ResultsWe analyzed a total of 2143 patients aged over 65 years from 10 institutions. The mean age was 74.2 ± 6.26 years (65–97), 1634 (76.2%) were men. Patients took a mean of 6.48 ± 2.46 medications (range 0–18), and polypharmacy was found in 1762 patients (82.2%). The number of patients who received PIMs at least once was 1579 (73.7%). The average number of PIMs used per patient was 1.31 ± 1.25 (0–7). PIM use ratio was 18.9 ± 0.15% (0–67%). The number of chronic diseases, and concurrent medication and polypharmacy were predictive factors associated with PIM use.ConclusionOur multi-institutional results show that a substantial proportion of elderly patients took PIMs when visiting the urology department. Factors associated with PIMs were the number of chronic diseases and polypharmacy. Medication use in elderly patients, especially in urology, should be monitored carefully. 相似文献
53.
54.
55.
《Research in social & administrative pharmacy》2019,15(10):1259-1265
BackgroundStudies have shown that a clinical medication review (CMR) reduces drug-related problems (DRPs), but the effects on clinical outcomes are less clear. Perhaps, CMRs in older persons could me more effective when they focus on patients’ personal goals and health-related complaints.ObjectiveThe aim of this study was to investigate whether goal attainment scaling (GAS) is a useful tool for determining goals and monitoring their attainment during CMR.MethodsThis study was an analysis based on data of the intervention group of the DREAMeR-study; a randomised controlled trial investigating the effects of CMR in primary care. 315 persons aged ≥70 years using ≥7 drugs were randomised to the intervention: a CMR focused on personal goals using GAS. Outcome measures were: percentage of persons with health-related goals, attainment of goals measured with GAS-scores after three and six months, type of health-related goals and implementation rates of recommendations for GAS-related DRPs and other DRPs.ResultsA total of 406 health-related goals were set for 283 of 315 included persons (90%). Of the 350 evaluated goals (86%), 37% was attained after three months and 43% after six months. The goals ‘reduce pain’ (n = 66, 16%), ‘improve mobility’ (n = 57, 14%) and ‘reduce number of pills’ (n = 37, 9.1%) were most prevalent. The implementation rate of recommendations for GAS-related DRPs was 81% compared to 62% for not GAS-related DRPs (p < 0.05).ConclusionGoal setting is important for prioritizing the most important problems during clinical medication review and Goal Attainment Scaling seems to be a useful tool for monitoring the attainment of these goals. 相似文献
56.
《Bulletin du cancer》2022,109(3):358-381
The development of tyrosine kinase inhibitors has revolutionized the treatment strategy in patients with non-small cell lung cancer with activating EGFR mutations, ALK or ROS-1 gene rearrangements. The Food and Drug Administration and European Medicines Agency have approved several inhibitors for the treatment of non-small cell lung cancer : five tyrosine kinase inhibitors targeting EGFR (erlotinib, gefitinib, afatinib, osimertinib and dacomitinib) and six tyrosine kinase inhibitors targeting ALK (crizotinib, céritinib, alectinib, brigatinib, lorlatinib and entrectinib). Interestingly, these tyrosine kinase inhibitor treatments are administered orally. While this route of administration improves the treatment flexibility and provides a comfortable and preferable option for patients, it also increases the risk of drug-drug interactions. The latter may result in changes in pharmacokinetics or pharmacodynamics of the tyrosine kinase inhibitors or their concomitant treatments, with subsequent risks of increasing their toxicity and/or reducing their effectiveness. This review provides an overview of drug-drug interactions with tyrosine kinase inhibitors targeting EGFR and ALK, as well as practical recommendations to guide oncologists and clinical pharmacists in the process of managing drug-drug interactions during the treatment of non-small cell lung cancer with tyrosine kinase inhibitors. 相似文献
57.
58.
Eri Ohara Yoshinori Bando Tomoji Yoshida Masaki Ohara Yutaka Kirino Naomi Iihara 《Research in social & administrative pharmacy》2021,17(6):1181-1197
BackgroundMultiple medication use among older patients is reported to increase fracture risk. But this association is unclear in different subgroups and has not been confirmed by a case–crossover study, which can eliminate measurable and unmeasurable time-invariant confounders.ObjectiveTo estimate the fragility fracture risk associated with concurrent use of multiple central nervous system (CNS) agents in older patients using a case–crossover design.MethodsThis study targeted almost all patients aged ≥65 years in Japan who incurred fragility fractures from May 2013 to September 2014, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB Japan). Conditional logistic regression analysis estimated the risk of fragility fracture associated with the daily number of CNS agents, including subgroup analyses stratified by sex, age, and fracture location.ResultsFor 446,101 patients, the adjusted odds ratios (ORs) of fragility fracture increased almost linearly with number of CNS agents; 0, 0–1, 1–2, 2–3, 3–4, 4–5, and >5: OR reference, 1.21 (95% confidence interval, 1.18–1.23), 1.40 (1.35–1.46), 1.58 (1.49–1.67), 1.89 (1.74–2.05), 1.80 (1.60–2.03), and 1.90 (1.61–2.23; trend p < 0.001), respectively. A similar trend was observed for several subgroups, especially in males and those aged ≥85 years, showing marked linearity.ConclusionsThe increased risk of fragility fracture associated with the use of multiple CNS agents was robust in older people in Japan. 相似文献
59.
中国已进入老龄化社会,共病是老年人群较为突出的公共健康问题。总结梳理老年人群共病领域研究现状,分析探讨相应策略对于老年共病人群的临床综合管理具有重要意义。本文重点从共病管理研究实践、共病诊疗模式、共病用药策略、共病医护团队及健康管理服务体系建设方面分析了该领域研究现状,同时提出建立以患者为中心的共病管理研究方案、推广应用老年共病评估工具、开展共病共有病因及机制研究、制订共病管理规范性指南/共识、借鉴中医学"以证统病""整体观念"思想、融合互联网+技术与智能可穿戴设备及开展共病早期风险评估与管理等应对策略,综合展望共病领域后期研究方向,以期为该领域进一步深入研究提供参考。 相似文献
60.
Chronic Pain Management in the Elderly 总被引:1,自引:0,他引:1
《Anesthesiology clinics》2019,37(3):547-560